Reduction of XXXX by @entity1289 inhibition.

@entity1 @entity644 @entity8 @entity1289 @entity3593
The effects of the @entity1289 ( @entity1289 ) inhibitor @entity3593 on blood pressure, @entity644 and renal hemodynamics were evaluated in 13 @entity1 with @entity8 of different origin. A comparison was made with the effects of conventional antihypertensive therapy. Both drug regimens significantly lowered blood pressure, while only after 12 weeks of treatment with @entity3593 , blood pressure was significantly lower than during conventional therapy. @entity3593 reduced @entity644 (by 61 +/- 40%), whereas conventional therapy had no significant effect on protein excretion. During the first eight weeks of treatment with @entity3593 , there was a comparable degree of blood pressure reduction with both treatment regimens, whereas urinary protein loss was significantly less during @entity1289 inhibition. There was only a nearly-significant positive correlation between the fall in @entity644 during @entity3593 and the concomitant decrease in mean arterial pressure. Glomerular filtration rate decreased from 26.3 +/- 11.6 to 20.6 +/- 9.4 ml/min during treatment with @entity3593 . This decrease was not correlated with the fall in @entity644 . A significant positive correlation existed between the fall in urinary protein excretion and both the decrease in overall renal vascular resistance, and the fall in filtration fraction. Although blood pressure lowering by itself could contribute to the antiproteinuric effect of @entity3593 , our results suggest that this effect of @entity1289 inhibition is also due to efferent (postglomerular) vasodilation. We conclude that the @entity1289 inhibitor @entity3593 effectively reduces blood pressure and @entity644 in @entity8 . The latter effect is not only the result of a lower blood pressure, but is probably also due to a fall in intraglomerular capillary pressure.
